Lv4
410 积分 2024-05-08 加入
Efficacy and safety of teclistamab in triple‐class exposed relapsed/refractory multiple myeloma: Pooled findings from three clinical cohorts and a retrospective cohort
7小时前
已完结
Impact of CD34 + cell infusion dose on immune reconstitution and survival in multiple myeloma after autologous stem cell transplantation
2天前
已完结
Navigating High-Risk and Ultrahigh-Risk Multiple Myeloma: Challenges and Emerging Strategies
1个月前
已完结
Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group
1个月前
已完结
International Myeloma Working Group Recommendations for the Diagnosis and Management of Myeloma-Related Renal Impairment
1个月前
已完结
Lymphocyte profile in peripheral blood of patients with multiple myeloma
1个月前
已完结
Immune profiles to predict bortezomib-based treatment response for multiple myeloma patients
1个月前
已完结
Safety and efficacy of apixaban for routine thromboprophylaxis in myeloma patients treated with thalidomide‐ and lenalidomide‐containing regimens
1个月前
已完结
Primary prevention of venous thromboembolism with apixaban for multiple myeloma patients receiving immunomodulatory agents
1个月前
已完结
Safety and efficacy of apixaban as thromboprophylaxis in myeloma patients receiving chemotherapy: A prospective cohort study
1个月前
已完结
皖公网安备34019202002308
